0000000000288761

AUTHOR

Ciccarese F

showing 3 related works from this author

Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre s…

2015

Background & Aims The role of hepatic resection for hepatocellular carcinoma (HCC) in different Barcelona Clinic Liver Cancer (BCLC) stages is controversial. We aimed at measuring the survival benefit of resection vs. non-surgical-therapies in each BCLC stage. Methods Using the ITA.LI.CA database, we identified 2090 BCLC A, B, and C HCC patients observed between 2000 and 2012: 550 underwent resection, 1046 loco-regional therapy (LRT), and 494 best supportive care (BSC). A multivariate log-logistic model was chosen to predict median survival (MS) after resection vs. MS after LRT or BSC. The results were expressed as net survival benefit of resection: (MS resection - MS LRT)/MS BSC. Resul…

Malemedicine.medical_specialtyCirrhosisCarcinoma HepatocellularLoco-regional therapieHepatocellular carcinomaSettore MED/12 - GASTROENTEROLOGIAHepatitis C virusKaplan-Meier Estimatemedicine.disease_causeGastroenterologyCohort StudiesLiver diseaseInterquartile rangeInternal medicinemedicineHumansBest supportive care; Cirrhosis; Hepatocellular carcinoma; Liver resection; Loco-regional therapies; Survival benefit; Aged; Carcinoma Hepatocellular; Cohort Studies; Female; Humans; Italy; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Prognosis; Treatment Outcome; Medicine (all); HepatologyBEST SUPPORTING CAREAgedNeoplasm StagingCirrhosiHepatologyPerformance statusLiver resectionbusiness.industryMedicine (all)CIRRHOISISCarcinomaLiver NeoplasmsHepatocellularMiddle Agedmedicine.diseasePrognosisBCLC StageTreatment OutcomeCirrhosisItalySurvival benefitHepatocellular carcinomaMultivariate AnalysisFemaleLoco-regional therapiesLiver cancerbusinessBest supportive careJournal of hepatology
researchProduct

Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma.

2017

Background and aims the Barcelona Clinic Liver Cancer intermediate stage (BCLC-B) of hepatocellular carcinoma (HCC) includes extremely heterogeneous patients in terms of tumor burden and liver function. Transarterial-chemoembolization (TACE) is the first-line treatment for these patients although it may be risky/useless for someone, while others could undergo curative treatments. This study assesses the treatment type performed in a large cohort of BCLC-B patients and its outcome. Methods retrospective analysis of 485 consecutive BCLC-B patients from the ITA.LI.CA database diagnosed with naive HCC after 1999. Patients were stratified by treatment. Results 29 patients (6%) were lost to follo…

SorafenibMaleNiacinamidemedicine.medical_specialtyStandard of careCarcinoma HepatocellularAntineoplastic AgentsGastroenterologyIntermediate stage03 medical and health sciences0302 clinical medicineHCC; BCLC-B; Intermediate stage; Treatment; HepatologyInternal medicinemedicineHumansChemoembolization TherapeuticHCCPropensity ScoreAgedNeoplasm StagingRetrospective Studiesintermediate stageHepatologytreatmentbusiness.industryPatient SelectionPhenylurea CompoundsLiver NeoplasmsSettore MED/09 - MEDICINA INTERNAStandard of CareHepatologyMiddle AgedSorafenibmedicine.diseaseSurvival AnalysisTreatment OutcomeItaly030220 oncology & carcinogenesisHepatocellular carcinomaPropensity score matchingMultivariate Analysis030211 gastroenterology & hepatologyFemaleLiver functionLiver cancerbusinessBCLC-Bmedicine.drug
researchProduct

Rise and fall of HCV-related hepatocellular carcinoma in Italy: a long-term survey from the ITA.LI.CA centres

2013

Background & Aims Hepatitis C virus (HCV) is the leading aetiological factor of HCC in the western world where, overall, its incidence is increasing, despite data suggesting an initial drop in some areas. The aim of this study was to evaluate epidemiology, clinical features and survival of HCV-related HCC (HCV-HCC) in a wide time range in Italy. Methods Multicentre retrospective study including 3695 patients prospectively recruited by the ITA.LI.CA group. Patients were classified into three subgroups according to aetiology (Group A[GA], pure HCV; Group B[GB], HCV + cofactors; and Group C[GC], non-HCV) and in 5 time cohorts (5 years each), according to the year of diagnosis. Age, gender, Chi…

Malemedicine.medical_specialtyCarcinoma HepatocellularCirrhosisHepatitis C virushepatitis C hepatocellular carcinoma cirrhosismedicine.disease_causeGastroenterologyGroup BSex FactorsInternal medicineEpidemiologyPrevalencemedicineHumansHEPATOCELLULAR CARCINOMACIRRHOSISRetrospective StudiesHepatologybusiness.industryIncidenceLiver NeoplasmsAge FactorsRetrospective cohort studyHepatitis Cmedicine.diseaseHepatitis CSurvival Analysisdigestive system diseasesSurgeryItalyHepatocellular carcinomaEtiologyFemalebusinessLiver International
researchProduct